An analysis conducted, more chances of developing heart failure will be there in women with advanced breast cancer who were treated with Roche's Avastin and this again got the troubles drug under a fresh controversy.

Patients who were a part of five clinical trials were analyzed by a team led by Dr. Toni Choueiri of Dana Farber Cancer Institute and Harvard Medical School in Boston.

As compared to about 0.4 per cent women who took a placebo, congestive heart failure was developed by 1.6 per cent of the women who took Avastin.

Choueiri said, "Overall, the risk is small, but it is definitely more than the placebo."

Avastin has an annual sale of $6 billion and it is considered as the world's best selling cancer drug and these findings gats people concerned about the drug.

Avastin not being approved for breast cancer was recommended by U. S. regulators last month. Only one kind of chemotherapy being limited to the drug's use was recommended by European authorities.

Survival in four clinical trials of patients with breast cancer is what the drug failed in but for fighting breast cancer and some other cancers, Avastin, or bevacizumab, has been approved.